NAD+ (nicotinamide adenine dinucleotide) biology — the essential coenzyme declining with age that regulates hundreds of metabolic processes, sirtuins, and PARP DNA repair enzymes — has created both a large consumer supplement market and a serious pharmaceutical research program, with the Longevity Market reflecting NAD+ as one of the most commercially significant longevity biology targets.

NAD+ decline with aging — the approximately fifty percent reduction in cellular NAD+ levels from youth to old age correlating with mitochondrial dysfunction, DNA damage accumulation, metabolic decline, and many hallmarks of aging — creates the scientific rationale for NAD+ restoration therapy. David Sinclair's (Harvard) and Johan Auwerx's (EPFL) research demonstrating NAD+ precursor supplementation restoring mitochondrial function and extending healthspan in animal models creating the academic foundation for the commercial market.

NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) supplement market — the direct NAD+ precursor supplements generating estimated one to two billion dollars annually in consumer sales — represent the most commercially established longevity supplement category. Elysium Health (Basis — NR plus pterostilbene), Tru Niagen (NR), David Sinclair's ProHealth NMN, and dozens of competing NMN/NR products creating the highly competitive NAD+ supplement market.

FDA's attempted NMN regulation as drug — the FDA's 2022 decision that NMN cannot be marketed as a dietary supplement because it is under investigation as a new drug (by Metro International Biotech) — represents the regulatory tension between pharmaceutical development and supplement market competition. The commercial implications of FDA's decision potentially restricting NMN supplement sales creating the regulatory risk that supplement companies navigate.

Do you think NMN and NR supplements provide clinically meaningful NAD+ restoration and health benefits in humans, or does the preclinical promise not translate to significant human benefit from oral supplementation?

FAQ

What is NAD+ and why does it decline with aging? NAD+ (nicotinamide adenine dinucleotide): essential coenzyme in every cell; roles: electron carrier in cellular respiration; substrate for sirtuins (longevity proteins), PARPs (DNA repair), CD38 (immune function); NAD+ decline with age: CD38 expression increasing with aging consuming NAD+; declining biosynthesis; increasing consumption from DNA damage accumulation; results: impaired mitochondrial function, reduced DNA repair capacity, reduced sirtuin activity; preclinical NAD+ restoration: remarkable improvements in multiple age-related conditions in mice; human data: more limited but showing metabolic and physical function signals.

What is the difference between NMN and NR as NAD+ precursors? NR (nicotinamide riboside): NAD+ precursor; oral absorption; enters cells via specific transporters; converted to NMN then NAD+; well-studied; patent held by ChromaDex (Tru Niagen); multiple Phase I-II human trials; NMN (nicotinamide mononucleotide): one step closer to NAD+ than NR; higher molecular weight; direct NMN transporter (Slc12a8) in some tissues; David Sinclair publicly taking NMN; multiple Japanese and US human studies; both increasing blood NAD+ levels in human trials; unclear if equivalent or one superior for tissue-specific NAD+ elevation; combined supplement formulations common.

#LongevityMarket #NAD #NMN #NicotinamideRiboside #LongevitySupplement #SirtuinActivation